Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
- Drug Discovery
- cell therapy
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 282952
Wnt is a key developmental pathway that affects the expression of multiple target genes.
Licensed Materials means proprietary materials of either University which are developed by either University as a result of research concerning the Licensed Invention.
IPSCIO Record ID: 328113
Licensors each have an assignment of WNT Compositions and Methods, collectively the invention, which involves the use of a gene that is active in the growth and development of tissues and cells.
IPSCIO Record ID: 203513
Biological Materials shall mean the proprietary materials developed in the laboratories of certain Drs. as a result of research concerning the licensed subject matter, identified including Polypepetides, Gene Sonic hedgehog (shh), Gene Indian hedgehog (lhh) and Gene Desert hedgehog (Dhh), together with any progeny, mutants or derivatives, to the extent that they contain a substantial portion of the original Biological Materials. Proprietary materials shall mean materials which are not generally available from another source and which are under the control of Licensor.
Sonic hedgehog is a protein that in humans is encoded by the SHH ('sonic hedgehog') gene. Both the gene and the protein may also be found notated alternatively as 'Shh'.Sonic hedgehog is one of three proteins in the mammalian signaling pathway family called hedgehog, the others being desert hedgehog (DHH) and Indian hedgehog (IHH). SHH is the best studied ligand of the hedgehog signaling pathway. It plays a key role in regulating vertebrate organogenesis, such as in the growth of digits on limbs and organization of the brain.
Milestone Products shall mean products which are not Licensed Products and are identified or discovered in material part through the use of processes or subject matter covered in a Claim or agonize or antagonize members of the hedgehog gene family or agonize or antagonize follistatin or incorporate a substantial portion of a Biological Material or which could not be made except by utilizing a Biological Material or are antibodies which bind to a hedgehog protein.
PATENT RIGHTS shall mean United States patent application Serial No. 08/136.748 filed October 14. 1993 and United States patent application Serial No. 08/176.427 filed December 30. 1993. United States Patent Application Serial No. 09/394.020. filed September 10,1999.
IPSCIO Record ID: 289171
Licensed Product means any device, composition, product or part of a product in the Licensed Field of Use, the manufacture, use, sale, offer for sale or import of which, but for the licenses granted herein, would infringe a Valid Claim of a Licensed Patent.
IPSCIO Record ID: 352695
– Allele-specific RNA Interference;
– In Vivo Production of Small Interfering RN As that Mediate Gene Silencing;
– RNA Interference for the Treatment of Gain-of-Function Disorders;
– Novel AAVs and Uses Thereof;
– CNS Targeting AAV Vectors and Methods of Use Thereof;
– Methods and Compositions for Controlling Efficacy of RNA Silencing;
– Methods and Compositions for Enhancing the Efficacy and Specificity of Single and Double Blunt-Ended siRNA; and,
– Methods and Compositions for Enhancing the Efficacy and Specificity of RNAi.
from the Field.
The gene therapy approach uses AAV (adeno-associated virus) vectors, which are modified, non-replicating versions of AAV, and which we believe are ideal vectors for CNS gene therapy.
The Licensee expects to utilize established and novel techniques for dosing and delivery of our AAV gene therapies to the CNS.